Gb Sciences

About Gb Sciences

Gb Sciences, Inc. (OTCQB:GBLX) is a phytomedicine-based research and biopharma drug development company creating patented, disease-targeted formulations of plant-inspired therapeutic mixtures for the prescription drug market through GbS Global Biopharma, our Canadian subsidiary. The ‘plant-inspired’ active ingredients in our therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices (cGMP). Gb Sciences' novel drug discovery platform has yielded five issued U.S. and three issued international patents, as well as 10 U.S. and 35 international patent-pending applications. In our drug development pipeline, we have four preclinical-stage programs and our lead Parkinson's disease therapeutic program is being prepared for a First-in-Man clinical trial. In addition to Parkinson's disease, Gb Sciences is developing therapeutics for neuropathic pain, cytokine release syndrome (CRS), Mast Cell Activation Syndrome (MCAS), and heart failure. Gb Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. https://gbsciences.com